Day 1 :
Keynote Forum
Colleen Huber
Naturopathic Cancer Society, USA
Keynote: Sugar and cancer: A 7-year, controlled study
Time : 09:15-09:45
Biography:
Colleen Huber NMD is a Naturopathic Medical Doctor in Tempe, Arizona. She was the Keynote Speaker at the 2015 Euro Cancer Summit, the 2016 World Congress on Cancer Therapy, and a Keynote Speaker at the 2016 and 2017 World Congress on Breast Cancer. She is President of the Naturopathic Cancer Society. She is a Naturopathic Oncologist and Fellow of the Naturopathic Oncology Research Institute. She authored the largest and longest study in medical history on sugar intake in cancer patients, which was reported in media around the world in 2014. Her other writing includes her book, choose your foods like your life depends on them, and she has been featured in the books America’s Best Cancer Doctors and Defeat Cancer. Her academic writing has appeared in The Lancet and Cancer Strategies Journal, and other medical journals. Her research interests are in the use of therapeutic approaches targeting metabolic aspects of cancer.
Abstract:
Introduction: Ingestion of glucose and malignant neoplastic growth has been established in animal studies for numerous types of cancer. Such studies examined mice and/or fewer than 20 human subjects and/or were retrospective. This study is a 7-year interventional study of 317 consecutive human cancer patients at one naturopathic cancer clinic, who were treated with cancerdisrupting nutrients and herbs, as well as abstention from sweetened foods as the dietary intervention.
Methods: Survival of sweetened food eaters vs abstainers among cancer patients was examined at one clinic over a sevenyear period. Since 2006, this clinic has recorded data on consumption of sugar and other sweeteners in cancer patients, and has consistently recommended, but never enforced, avoidance of sweetened foods, except with extracts of the plant Stevia rebaudiana, which does not contain saccharides or sugar alcohol. In this controlled interventional study, the diets and outcomes are reported for all 317 patients with a diagnosis of cancer who were treated at the clinic, and who stayed at least two weeks in treatment. All results are reported in this paper.
Results: Achievement of remission was quite different for the following two categories: all patients: 151/317=48% and those who ate sweetened foods: 9/29=31%. The difference between these two groups was much stronger for the cohort of patients who continued treatments until either remission or death. Comparing all patients who were steadfast in the recommended treatments with the sweetened food eaters who were steadfast in all but dietary recommendations, 151/183=83% of all completely steadfast patients achieved remission, but only 9/25=36% of the steadfast sweetened food eaters achieved remission. Remission was defined as no visibly active tumor on MRI imaging of the same area that had previously active tumor growth. Of all patients who were steadfast in the treatments (including the sweetened food eaters), 32/183=17% died while still under the care of the clinic, but considering only the sweetened food eaters who otherwise consistently pursued the recommended treatments, 16/25=64% died. Follow-up studies since 2014 found similar survival differences among the two groups studied.
Conclusion: In this first-ever, long-term, interventional study of glycemic restriction in hundreds of cancer patients, we found that sweetened foods (other than stevia-sweetened foods) were highly correlated with patient mortality across all types and all stages of cancer. Stevia is therefore recommended as the only sweetener to be used by cancer patients.
Keynote Forum
Jie Xu
MD Anderson Cancer Center, USA
Keynote: Expression of programmed cell death 1 ligands in histiocytic and dendritic cell neoplasms
Time : 09:45-10:15
Biography:
Jie Xu has received her MD from Hubei Medical University and her PhD from the University of Alabama at Birmingham. She is currently an assistant professor in the Department of Hematopathology at the University of Texas MD Anderson Cancer Center. She is board certified by the American Board of Pathology in Anatomic Pathology, Clinical Pathology, and Hematology. she has been actively participating in multiple research projects in tumors of hematopoietic and lymphoid tissue, and cancer, which has led to 48 research papers, 39 presentations at the national and international conferences, and multiple awards. Her major research interests include diagnostic and prognostic factors in lymphoma and leukemia and the potential therapeutic targets for hematopoietic neoplasms.
Abstract:
PD-1 (programmed cell death protein 1) is expressed on activated T cells. The ligands (PD-L1 or PD-L2) on tumor cells or antigen presenting cells bind to PD-1 and results in reduced T cell activation and inhibited immune responses. Antibodies targeting PD-1 or PD-L1 elicit antitumor immunity in a subset of patients with solid tumors including melanoma, renal cell carcinoma, non-small cell lung cancer and hematopoietic tumors such as classical Hodgkin lymphoma, and clinical response correlates with PD-1 ligand expression by malignant or immune cells within the tumor microenvironment. Histiocytic and dendritic cell sarcomas are malignant neoplasms with high morbidity and mortality; they are rare and can be difficult to diagnose. We examined the expression of PD-1 ligands on histiocytic and dendritic cell sarcomas. Seven of 14 histiocytic sarcomas (HS) (50%), 2 of 5 interdigitating dendritic cell sarcomas (IDS) (40%), 10 of 20 follicular dendritic cell sarcomas (FDS) (50%), and none of 9 blastic plasmacytoid dendritic cell neoplasms (BPDCN) were positive for PD-L1. Eleven of 20 (55%) follicular dendritic cell sarcomas were also positive for PD-L2. Our results suggest that PD-L1 and PD-L2 IHC may prove useful in establishing or confirming the diagnosis of histiocytic and dendritic cell sarcomas. Given that patients with histiocytic and dendritic cell sarcomas are generally resistant to conventional chemotherapy, checkpoint blockade may prove a more effective alternative. In summary, PD-L1 and PD-L2 are useful new markers for identifying select histiocyte and dendritic cell neoplasms and reveal novel patient populations as rational candidates for immunotherapy.
Keynote Forum
Andrei L Gartel
University of Illinois at Chicago, USA
Keynote: FOX(M1) and cancer
Time : 10:15-10:45
Biography:
Andrei L Gartel, PhD, is an Associate Professor in the Department of Medicine at the University of Illinois at Chicago and is the academic editor of PLOS ONE. He is the author of 90 peer-review publications that include more than 25 reviews. He has more than 11,000 citations and his h-index is 41. His scientific interests include cancer, regulation of oncogenic transcription factors FOXM1, protein-protein interactions; cell cycle and regulation of CDK inhibitor p21. Specifically, his lab is interested in the identification of new FOXM1 inhibitors. He received his funding from NIH, DOD and private companies/foundations.
Abstract:
FOXM1 is an oncogenic transcription factor that is overexpressed in the majority of human cancers and is a potential target for anticancer drugs. We identified proteasome inhibitors as the first type of drugs that target FOXM1 in cancer cells. Moreover, we found that HSP90 inhibitor PF-4942847 that does not act as proteasome inhibitor also suppresses FOXM1. Chaperone HSP70 is induced after treatment with both proteasome/HSP90 inhibitors and after heat-shock stress and we identified this chaperone as a novel negative regulator of FOXM1 after proteotoxic stress. We showed that FOXM1 and HSP70 interact in cancer cells following proteotoxic stress and FOXM1/HSP70 interaction led to inhibition of FOXM1. We have previously shown that FOXM1 interacts with nucleophosmin (NPM) in cancer cells and NPM determines the cellular localization of FOXM1. Mutations in NPM1 result in cytoplasmic re-localization of NPM (NPM1mut) and favorable outcome for the patients. We found the evidence that improved outcomes in the subset of NPM1mut AML may be partially explained by the cytoplasmic re-localization and consequent functional inactivation of FOXM1. First, we confirmed the co-localization of FOXM1 and NPMmut in the cytoplasm of AML patients bone marrow biopsies and determined a strong cytoplasmic expression of FOXM1 only in NPM1mut AML cells. We also showed an important role of FOXM1 in chemo-resistance in leukemia cell lines with nuclear, but not cytoplasmic FOXM1. These data imply that suppressing of FOXM1 in AML could increase sensitivity to standard chemotherapy.
Keynote Forum
Marja T Nevalainen
Medical College of Wisconsin, USA
Keynote: Novel small-molecule Stat5 Inhibitor for further optimization and clinical development for cancer therapy
Time : 11:00-11:30
Biography:
Marja Nevalainen, MD, PhD is an internationally recognized leader in the field of cytokine and steroid hormone signaling in prostate cancer. Dr Nevalainen holds the title of Eminent Scholar at MCW. She is also Director of Prostate Cancer Center of Excellence at MCW Cancer Center, which is a multi-disciplinary hub for prostate cancer research with an international collaborative network. Dr Nevalainen serves as Assistant Dean for Research at MCW, and Associate Director of Education for the MCW Cancer Center. Her primary appointment is in the Department of Pathology, and a secondary appointment in the Department of Pharmacology and Toxicology.
Abstract:
Jak2-Stat5 signaling plays a significant role in promoting growth and progression of Bcr-Abl-driven hematological malignancies as well as prostate cancer. Bypassing tyrosine kinases compelled for Stat5a/b phosphorylation would be favourable for therapy development for Stat5a/b- controlled cancers. To identify small-molecule inhibitors of Stat5a/b for lead optimization and therapy development, in silico screening of chemical structure databases combined with medicinal chemistry was used for identification of a group of small-molecule forestalling to block SH2-domain-mediated docking of Stat5a/b to the receptor-kinase complex and subsequent phosphorylation and dimerization. The lead compound Inhibitor of Stat5, IST5-002, (IST5) binds directly to the SH2-domain of Stat5 in fluorescence polarization assays. We additionally tried the viability of the lead-compound IST5 in exploratory models and patient examples of two best-known Stat5a/b-driven tumors, prostate cancer (PC) and interminable myeloid leukemia (CML). IST5 forestalled both Jak2 and Bcr-Abl-interceded phosphorylation and dimerization of Stat5a/b, and specifically hindered the transcriptional action of Stat5a (IC50 1.5μM) and Stat5b (IC50 3.5μM). IST5 suppressed nuclear translocation of Stat5a/b, binding to DNA and Stat5a/b target gene expression. IST5 had no significant inhibitory activity on a panel of 52 kinases, including Jak2 and Abl. Importantly, no signs of toxicity were noted at the dose of 100 mg/kg in acute or chronic toxicity studies conducted in mice. IST5 incited broad apoptosis of PC cells, weakened development of PC xenograft tumors and prompted cell demise in quiet inferred PCs when tried ex vivo in explant organ societies. Critically, IST5 initiated hearty apoptotic passing of imatinib-delicate as well as imatinib-safe unending myeloid leukemia (CML) cell lines and essential CML cells from patients. IST5 gives a lead structure to advance synthetic alterations for clinical improvement for Stat5a/b-driven strong tumors and hematological malignancies.
Keynote Forum
Magnus S Magnusson,
University of Iceland, Iceland
Keynote: Self-similarity and T-patterns from Cell City to the only big-brain mass-societies formed in a recent eye-blink: Proteomics as bio-sociology
Time : 11:30-12:00
Biography:
Magnus S Magnusson, Research Professor, PhD in 1983, University of Copenhagen. Author of the T-pattern model initially focused on the real-time organization of behavior and has co-directed DNA analysis. Numerous papers and invited talks at international mathematical, neuroscience, proteomics, bioinformatics and science of religion conferences and at leading universities in Europe, USA and Japan. Deputy Director 1983-1988, Anthropology Laboratory, National Museum of Natural History, Paris. Then repeatedly invited temporary Professor in psychology and ethology (biology of behavior) at the University of Paris (V, VIII & XIII). Since 1991, Founder and Director of the Human Behavior Laboratory, University of Iceland. Works in formalized collaboration between now 32 European and American universities based on “Magnusson’s analytical model” initiated at University René Descartes Paris V, Sorbonne, in 1995.
Abstract:
This talk concerns spatial and temporal self-similarity across more than nine orders of magnitude, implicating a self-similar fractal-like pattern, called T-pattern, a natural or pseudo-fractal pattern, recurring with statistically significant translation symmetry (Magnusson et al. eds. 2016). It is here presented in the order realized within a longstanding primarily ethological (i.e. biology of behavior) project beginning in the early 1970’s concerning social interaction and organization in social insects and primates including humans and inspired mainly by the work of Lorenz, von Frisch and Tinbergen for which they shared a Nobel Prize in Medicine or Physiology in 1973. The smallest animals concerned in their ethological work were social insects and there was no implication of self-similarity. The present project has focused on developing time pattern definitions and corresponding detection tools resulting in the T-pattern type and corresponding detection algorithms implemented as the THEME software, which has allowed their abundant detection (Casarrubea et al., 2015), in many kinds of animal and human behavior and interactions and later in neuronal interactions within living brains (Nicol et al.), thus showing T-patterned self-similarity of temporal interaction between and within brains. Apparently, the RNA world invented its evolving external memory as the purely informational T-patterned DNA strings and now there is only a DNA world. Similarly, humans invented their evolving external memory as the purely informational T-patterned strings of written language making possible very recently and in a biological eye-blink the development of modern science and technology and the creation of extremely populous and complex human mass-societies, the only mass-societies among large-brained animals and now all based on T-patterned text strings. Protein and human mass-societies seem to be the only ones using such durable long memory strings external to their citizens. Strings that are highly standardized with parts being massively copied, distributed, promoted and even enforced such as those among humans called legal or holy. Both Human and protein mass-societies create their specialized citizens using various sub-sections of the external T-patterned memory strings. Extensive temporal and spatial self-similar patterning thus seems to exist in form and function from nano to human temporal and spatial scales regarding transient nonverbal behavior and its more durable spatial traces or products such as texts, all patterned in a way reflecting the fundamental and extremely ancient molecular structure of their creators.
- Natural methods for Cancer treatment | Targeted Cancer Therapies| Hematology-Oncology| Oncogenomics |Cancer Pharmacology| Oncology | Cancer Biology | Cancer Screening| Immune Checkpoint Inhibitors | Cancer Research & Cancer vaccines
Location: Hillcrest-II
Chair
Marja T Nevalainen
Medical College of Wisconsin, USA
Session Introduction
Ketki Tendulkar
University of Nebraska Medical Center, USA
Title: Effects of newer anti-cancer agents on the kidney
Biography:
Ketki Tendulkar, MBBS is an assistant professor with the Division of Nephrology at the University of Nebraska Medical Center. She has completed her medical school in 1990 from University of Mumbai, India. Thereafter, she came to the United States for further training and completed her residency and fellowship in Nephrology in 2010. After starting as Internal Medicine- Nephrology faculty at the University of Nebraska Medical Center she has published in the emerging field of Onco-nephrology. Her research interests have led to the publications outlined above in this field which deals with cancer-related acute and chronic kidney problems. She is also actively involved in the kidney donor evaluation at the University hospital.
Abstract:
The past few years have seen several important successes in the management of cancer patients with the approval of molecularly targeted agents and immune checkpoint inhibitors for a variety of malignancies. Further, in 2017, we saw the advent of a new form of immunotherapy known as CAR-T cell therapy being developed for hematological malignancies. Despite these advances, our scientists, clinicians, and patients need to be aware that only a small percentage of patients actually benefit from such treatments. Even though the side effect profile of these newer drugs is much better than that seen with the conventional cytotoxic chemotherapy, we cannot overlook the unique, potentially life-altering harmful side-effects associated with these agents. These renal side-effects evolve from the augmentation of the immune system-mediated recognition and targeting of tumor cells. Vascular endothelial growth factor (VEGF) inhibiting agents, such as the monoclonal antibody bevacizumab, and anti-VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKIs) have the potential to cause elevated blood pressure and proteinuria leading to long-term chronic kidney disease. In addition, there can be off-target effects of these therapies which can range from electrolyte disorders to acute kidney injury. Some others like rituximab, an anti-CD20 monoclonal antibody, and everolimus, a mammalian target of rapamycin (mTOR) inhibitor, can also cause acute kidney injury. Severe acute kidney injury related to cytokine release syndrome, seen with immunotherapy, including CAR-T cells, need aggressive treatment with crystalloid intravenous fluid resuscitation and even renal replacement with dialysis may be indicated. Acute interstitial nephritis is a most common form of renal toxicity with immune checkpoint inhibitors, so far with minimal change, IgA and membranous nephropathy being rarer complications. With increasing options for treating patients with a history of a kidney transplant and cancer, post-kidney transplant rejection can also be an important decision for patients who fear the thought of returning to dialysis. So decision-making regarding stopping or modifying cancer therapy for the overall benefit, despite renal toxicity, continues to remain a challenge. In clinical practice, kidney biopsy to get a tissue diagnosis may be the answer to facilitate management plans in such situations.
Wassil Nowicky
Ukrainian Anti-Cancer Institute, Austria
Title: Affinity of the anti-cancer preparation NSC631570 (Ukrain) to the cancer cells
Biography:
Wassil Nowicky — Dipl. Ing., Dr. techn., DDDr. h. c., Director of “Nowicky Pharma” and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). Has finished his study at the Radio-technical Faculty of the Technical University of Lviv (Ukraine) with the end of 1955 with graduation to “Diplomingeniueur” in 1960 which title was nostrificated in Austria in 1975. Dr. Wassil Nowicky became the very first scientist in the development of the anticancer protonic therapy and is the inventor of the preparation against cancer with a selective effect on basis of celandine alkaloids “NSC-631570”. He used the factor that cancer cells are more negative charged than normal cells and invented the Celandine alkaloid with a positive charge thanks to which it accumulates in cancer cells very fast. Author of over 300 scientific articles dedicated to cancer research. He is a real member of the New York Academy of Sciences, member of the European Union for applied immunology and of the American Association for scientific progress, honorary doctor of the Janka Kupala University in Hrodno, doctor “honoris causa” of the Open international university on complex medicine in Colombo, honorary member of the Austrian Society of a name od Albert Schweizer. He has received the award for merits of National guild of pharmacists of America. the award of Austrian Society of sanitary, hygiene and public health services and others.
Abstract:
It is well known all living cells have a membrane potential of about -60 to –100mV. The negative sign of the membrane potential indicates that the inside surface of the cell membrane is relatively more negative than the immediate exterior surface of the cell membrane. Researchers at the University of Natural Resources and Life Sciences, Vienna (Austria) revealed human osteosarcoma cells to have a high capacity to absorb NSC631570 while absorption in normal endothelial cells was considerable lower under the same experimental conditions. This selective uptake of NSC631570 in the cancer cells has been confirmed due to its unique prop-erty to auto fluorescence under UV light. A study examined how NSC631570 affects the electro kinetic potential (EKP) of malignant and benign cells. The EKP of the Ehrlich’s carcinoma cells dropped after incubation with NSC631570. The EKP decrease of normal cells was less pronounced. The cytotoxic effect of NSC631570 was examined on two primary pancreatic cancer cell lines (PPTCC), fibroblasts from ductal pancreatic cancer tissue samples (F-PDAC) and an immortalized ductal epithelial pancreas cell line (HPNE). Cytotoxicity was established by means of Cell Titer 96 kit. In the tests with primary pancreatic cancer cell lines the modulation of NSC631570 absorption in the medium was determined with the help of the fluorescence of NSC631570 under UV light. The fluorescence test showed that carcinoma cells absorbed more of the preparation than fibroblasts and normal epithelial cells. The selective accumulation of NSC631570 in the cancer cells explains its favorable safety profile and high therapeutic index of 1250.
Narjiss Akerzoul
Mohammed V University Of Rabat, Morocco
Title: Oral Mucocitis: A very common oral side effect of radio-chemotherapy
Biography:
Narjiss Akerzoul received her Doctorate of Dental Surgery (DDS) from Mohammed V University of Rabat-Morocco in the year 2011. Later she worked as a General practitioner Dentist in Oral Health Center of Guelmim City, Morocco. Later in 2013, she started her residency program in Oral Surgery and Oral Medicine and OroFacial Pain in the Consultation Center of Dental Treatments of Rabat. Later on, she completed her Diploma in Biostatistics and Research Methodology during 2014-2015. She achieved her Board examination of Oral Surgery and Oral Medicine and OroFacial Pain in July 2017 and became An Oral Surgeon Fellow. She has authored and co-authored many International Publications in the field of Oral Surgery, Oral Medicine and Oral Oncology. She has been an editorial member in Department of Oral and Maxillofacial Surgery of the International Journal of Oral Health and Medical Research (IJOHMR), Reviewer and Editor in Omics Group Biomedical Journal. .
Abstract:
Introduction: Oral mucositis is a frequent adverse effect of cytotoxic treatments by chemotherapy or radiotherapy. At the moment, there is no validated consensus for preventive or curative care.
Aim: To carry out a state of the management of chemo-induced mucositis.
Materials and Methods: Our study is a retrospective observational one, carried on 40 patients in two departments: dental service, and radiotherapy service of the National Institute of Oncology (INO) of Rabat, as well as in the Oral Surgery department of the Consultation Center of Dental Treatment of Rabat. The included patients were treated with radiotherapy +/- highly mitogenic chemotherapy. The evaluation criteria were: Age, sex, living environment, oral health, type of cancer treatment and others.
Results: Among the 40 patients included, 5 subjects developed mild grade 1 mucositis, grade 2 interested a group of 17 subjects, 14 patients developed grade 3 mucositis, and finally 4 subjects developed severe grade 4 mucositis. Preventive treatment was introduced in only 11 patients. Of the 40 cases, 33 were treated with curative treatment.
Discussion: After analysis of the results, there was no correlation between the type of pathology treated, the cytotoxic treatment used and the management modalities of the mucositis.
Conclusion: Although the results were very disparate, they will enable us to evolve the practices, validating proposals of protocols of care in a multidisciplinary working group. A new study could then be carried out to evaluate the effectiveness of these protocols.
Joseph C Glorioso
University of Pittsburgh School of Medicine, USA
Title: Herpes simplex virus oncolytic vectors (oHSV) armed with the NKG2D ligand ULBP3 enhances treatment of gliomas
Biography:
Joseph C Glorioso began his career at the University Of Michigan School Of Medicine, Ann Arbor, MA, USA (1976–1989), where he became Professor of Microbiology and Immunology and Assistant Dean for Research and Graduate Studies. He subsequently moved to the University of Pittsburgh, School of Medicine, and Pittsburgh, USA, where he served as Chair and the McElroy Professor of Biochemistry until 2009. He is a former president of the American Society of Gene and Cell Therapy and serves as the American Editor of Gene Therapy. His research focuses on molecular genetic aspects of herpes simplex virus (HSV) pathogenesis and the development of HSV gene vectors for treatment of chronic pain, neuropathy, and cancer.
Abstract:
Glioblastoma (GBM) is an incurable brain tumor for which the standard of care is not effective. Oncolytic viral therapies are under development to destroy GBM using engineered viral vectors that preferentially replicate in tumor cells. Although early phase trials have reported sporadic successes, improvements in vector design are needed to improve therapeutic efficacy. Effective viral therapy requires vectors that induce virolysis and promote anti-tumor immunity. This outcome is particularly challenging in GBM because glial malignancies are immunologically cold, and embedded in a profoundly immunosuppressive microenvironment. We have focused on the development of oHSV because these vectors (i) are highly virolytic for GBM, potentially releasing immunogenic cell debris, (ii) can be rendered safe without compromising virus lytic activity and (iii) can be engineered to express multiple immunomodulatory transgenes capable of activating innate and acquired anti-tumor responses. Here we describe an advanced oHSV vector armed with ULBP3, an activating NK cell (NKG2D) ligand that is often down-regulated as an immune escape mechanism in glioma. We tested the hypothesis that the expression of ULBP3 from an oHSV could activate NK cells and thereby improve the efficacy of GBM oncolytic virotherapy. Using human-derived glioma stem cells and a mouse glioma cell line, we demonstrated that infection of multiple cell lines with oHSV-ULBP3 significantly improves NK cell-mediated cytolysis in vitro. We then tested the therapeutic efficacy of an oncolytic vector armed with ULBP3 in a xenogeneic nude mouse model using the GBM-30 human glioma cell line. We observed that this new vector displayed an improved therapeutic profile compared to the parental unarmed vector (80% vs 40% long-term responders). Further studies using a GL261N-based orthotopic syngeneic model demonstrated that ULBP3 expression induced infiltration of cytotoxic CD8 T cells, suggesting that ULBP3 can be a potent inducer of both innate and acquired immunity. Our ongoing studies will determine whether a ULBP3 expression can enhance long-term animal survival in an NK cell or CD8 T cell-dependent manner.
James Vaidyan
Ayurveda Vaidyasala, Center for Cancer treatment, India
Title: Indian treatment for Leukemia and other cancers
Biography:
James Vaidyan is a traditional Ayurveda Vaidya with experience of more than 40 years in treating different diseases including cancers. (Vaidya means traditional doctor.) he is a doctor for many generations, holding through many generations, leaves which are detailing esoteric Vedic science of life. He treated and cured many patients suffering from bad stages of leukemia and other kinds of cancers.
Abstract:
I am a traditional Ayurveda practitioner (Vaidya) treating different types of cancers and leukemia. Chemotherapy can be avoided by opting for Ayurveda treatment. Remission is faster, without debilitating negative side effects. An intricate course of repeated refining, elaborate processing, and enrichment of highly efficient manner. A patient recovering from diseases through such treatment is becoming refined physical being and the body system totally regenerated. The basic principle of the methodology of this treatment is to strengthen and equip our own T cells in the blood; they become capable to fight against cancer. Antibody proteins are produced automatically and destroy cancer cells, without damaging other parts of the body. Medicines are prepared through elaborate processing. We are following the same procedures that have been practiced by the ancient Maharishis and masters. I have treated many cancer patients- different types of cancers including leukemia. Patients are improving much faster than what is happening in the best hospitals anywhere in the world. Even in salvage treatment, patients come back to life. The quality of life that they are enjoying during and after the treatment is tremendously different from how cancer patients live and suffer under chemotherapy and radiation treatment. It is my sincere request to the international scientific community to focus on how these practices that lie outside conventional science may be appropriately utilized and further researched. I am seeking right people/ Universities /Research Institutions for Collaboration and knowledge transfer for better utilization of this knowledge for the benefit of entire humanity.
Ozge Sezin Somuncu
Bahcesehir University, Turkey
Title: Exosomes of Human Melanoma Cells Induce Cancer Development in Human Dermal Cells through Rab27a and c-Met
Time : 15:15-15:40
Biography:
Ozge Sezin Somuncu has completed her PhD in the year 2017 at the age of 25 years from Yeditepe University/Turkey. She had a short post-doctoral fellowship in Queen Mary University London and shortly after she had an offer to develop her career as an assistant professor in Turkey. She is currently an Assistant Professor at BahçeÅŸehir University Faculty of Medicine. She is also the principal investigator of SOMUNCU Lab. Se has published 4 papers in reputed journals, 6 submitted manuscripts in 2018, she also has an accepted patent application, running 10 projects and applied for a COST Action. She has been serving as a reviewer in the Journal of Psychiatry and Psychopharmacology. She has collaborations with Queen Mary University London and Harvard Medicine Opthalmology Department.
Abstract:
Exosomes are small membrane-derived vesicles that transmit DNA constituents, mRNAs, microRNAs and proteins from donor cells to a receiver cell. Many divergent cells comprising mesenchymal cells, immune cells, and cancer cells discharge exosomes. Studies show that cancer cell exosomes create the entry and reprogramming of essentials connected to the tumor environment. A reference study established that melanoma-derived exosomes convey diverse proteins such as c-Met and Rab27a, which indicate a melanoma mark. Increased Met expressions in serum exosomes have thought to be a predictor of disease progression. Meanwhile, Rab27a has identified to be important in exosome discharge. Decreased expressions of Rab27a in human melanoma cells determined to diminish exosome release. This project aims to examine the effects of downregulation and upregulation of Rab27a and c-Met in human melanocytes by utilizing the isolated exosomes from a malignant melanoma cell lineage. Throughout the analysis of cancer-like formation; different protocols covering gene transfections, flow cytometry analysis of the transfection efficiency, Annexin-V apoptosis assays, tube formation assays, ELISA assays and gene expression profiling were performed. According to the results, exosomes derived from cancer cells conveyed information to healthy melanocytes/keratinocytes and induced cellular reaction with Met and Rab27a overexpression, therefore silencing their genes may be a beneficial approach for future treatment possibilities. The developing molecular contextual of melanoma exosomes and their implications for improved management of melanoma patients can be an astonishing therapeutic methodology for future actions.
G Aguirre
Hakken Enterprise S.A. de C.V., Mexico
Title: GanplexTM and Kimera-TestTM: Biotechnological screening tools designed identify human cancer-related virus and SNPs in non-invasive samples.
Biography:
Gisela Aguirre (MSc and PhD in Genetics & Molecular Biology), with bold principles and values, bets for the creation of a new paradigm of developing Science in Mexico. During the last five years, she has dedicated her talent and energy to the creation of a young scientific team and a has become Founder & CEO of startups in Mexico and USA, with more than 20 people dedicated to the development of technologies for affordable in vitro diagnostics tools for HIV, HPV, respiratory and gastric pathogens, aneuploidies in human embryos and cancer genetic propensity detection..
Abstract:
Most efforts of allopathic medicine are directed to treat diseases. This path has proved to be costly when chronic diseases, such as cancer and its associated viral co-morbidities, need to be treated and monitored in the long term. Hence, the development of prevention-oriented medicine may reduce the magnitude of the financial burden associated with practicing remedy-based medicine. GanplexTM and Kimera-TestTM, the prime products of Hakken Enterprise, were then conceived to identify individuals with high genetic risk of developing cancer before the disease becomes symptomatic. GanplexTM and Kimera-TestTM take advantage of DNA extracted from saliva and urine samples to identify cancer-related viruses and SNPs through multiplex assays in a single reaction. At the current stage of development, both assays identify cancer-related SNPs and the viral sequences with a sensitivity, specificity, and confidence higher than those reported for Sanger’s sequencing. Both assays require small DNA quantities to begin with and no purification of PCR products prior hybridization. This shortens to approximately 7 hours the time to provide a result. Hence, GanplexTM and Kimera-TestTM are biotechnological tools that provide the genetic information needed to identify individuals under risk of developing cancer, a circumstance that would help in personalizing cancer preventing protocols and introducing precision medicine into everyday’s life. This work was financed by CONACyT (Grant No. 250884, 230066).
Narjiss Akerzoul
Mohammed V University Of Rabat, Morocco
Title: Kaposi sarcoma and human herpus virus type 8: A rare case and review of the literature.
Biography:
Narjiss Akerzoul received her Doctorate of Dental Surgery (DDS) from Mohammed V University of Rabat-Morocco in the year 2011. Later she worked as a General practitioner Dentist in Oral Health Center of Guelmim City, Morocco. Later in 2013, she started her residency program in Oral Surgery and Oral Medicine and OroFacial Pain in the Consultation Center of Dental Treatments of Rabat. Later on, she completed her Diploma in Biostatistics and Research Methodology during 2014-2015. She achieved her Board examination of Oral Surgery and Oral Medicine and OroFacial Pain in July 2017 and became an Oral Surgeon Fellow. She has authored and co-authored many International Publications in the field of Oral Surgery, Oral Medicine and Oral Oncology. She has been an editorial member in Department of Oral and Maxillofacial Surgery of the International Journal of Oral Health and Medical Research (IJOHMR), Reviewer and Editor in Omics Group Biomedical Journal.
Abstract:
Kaposi sarcoma (KS) is a multifocal angioproliferative disorder of vascular endothelium, usually described in HIV positive patients, and primarily affecting mucocutaneous tissues with the potential to involve viscera. Four clinical variants of classic, endemic, iatrogenic, and epidemic KS are described for the disease, each with its own natural history, site of predilection, and prognosis. All forms of Kaposi sarcoma may manifest in the oral cavity and Kaposi sarcoma-associated virus (KSHV), also known as Human Herpes Virus type 8, appears essential to the development of all clinical variants. In the absence of therapy, the clinical course of KS varies from innocuous lesions seen in the classic variant to rapidly progressive and fatal lesions of epidemic KS. Our case report provides an overview of clinical aspects, pathogenesis, and treatment about a non-HIV positive patient presenting the classic form of KS related to HHV8.
Karine Breckpot
Vrije Universiteit Brussel, Brussel
Title: TriMix and antigen mRNA based vaccination
Biography:
Karine Breckpot has completed her PhD on genetically engineered dendritic cell vaccines in 2004 at the VUB (Belgium) and continued this line of research during her postdoctoral studies performed at VUB (Belgium) and the University College London (UK). She is a tenure track professor at the VUB, member of the faculty and research board, and president of the ethical committee for use of laboratory animals. She is a recognized expert in the field of immunotherapy as evidenced by her list of publications, patents, invited lectures, awards and presence in grant review committees.
Abstract:
Our immune system can detect and destroy cancer cells. However, growing cancer cells camouflage themselves as well as possible, blocking the attack of the immune system, or worse, they hijack certain cells of the immune system and turn them into cancer-promoting cells. In an attempt to stop this process, scientists want to boost the immune system. This can be done through cancer vaccination. The rationale is to provide the immune system with the identification card of cancer cells (tumor antigens) as well as an adjuvant to alarm the immune system. Several cancer vaccination strategies have been developed, among which the use of dendritic cells engineered in the laboratory using mRNA. We studied mRNA as a tool to deliver tumor antigens and immune modulating proteins, in particular, a mix of three mRNA molecules encoding the co-stimulatory molecule CD70 and two DC activation stimuli, CD40 ligand, and active TLR4 referred to as TriMix mRNA. Vaccination of stage III/IV melanoma patients with this dendritic cell vaccine have proven to be safe and well tolerated, to induce tumor antigen-specific immune responses and more importantly to induce objective clinical responses in over a quarter of patients. Although promising, ex vivo engineered cell-based vaccines are patient-specific and therefore time and money consuming. To generate a widely applicable cancer vaccine, it is important to immediately activate the dendritic cells in the patient's body. Therefore we studied several ways to deliver tumor antigen and/or TriMix mRNA to dendritic cells in situ. We studied several routes of delivery, including intranodal, intratumoral and intravenous. Linked to the systemic delivery of mRNA we studied several modes of mRNA encapsulation, including the use of lipids and polymers. The results of these studies will be presented and discussed in view of the current state-of-the-art.